Israel based Zebra Medical Vision, the deep-learning medical imaging analytics company, has partnered with Apollo Hospitals Group to deploy its software to assist Apollo Hospitals doctors with efficient and accurate diagnoses of COVID-19, by leveraging the company’s AI1™ platform.

In March 2019, Zebra-Med announced a collaboration with Apollo Hospitals chain, deploying AI-based tools at scale across India, supported by India-Israel Industrial R&D and Technological Innovation Fund. Following the deployment of the intracranial hemorrhage, the AI COVID-19 solution will enable future collaboration on additional medical findings, such as tuberculosis (TB).

While laboratory testing has served as the first line of diagnostics during the coronavirus crisis, these tests have limited accuracy and do not indicate the state of disease progression. Zebra-Med’s software offers a faster alternative for detection of COVID-19 when PCR testing is unavailable or delayed, monitoring patients with COVID-19, as decision support for the allocation of ER, ICU resources and quantifies the disease burden and its progression.

The AI solution for COVID-19 leverages Zebra-Med’s GGO (Ground-Glass Opacities) patented algorithm, which is a dominant imaging feature of COVID-19 pneumonia and modified it to include consolidations and provide an automated indication and quantification of suspected COVID-19 findings on standard chest CTs, both contrast and non-contrast, by measuring the percentage of affected lung-burden volume relative to the entire lung volume, segmentation of the suspected findings, and classification.